Keystone Heart
Keystone Heart Ltd 是一家醫學設備公司,開發和生產腦保護裝置,從而減少心血管手術中腦損傷引發的中風、神經認知退化和癡呆的風險。該公司主要注重保護大腦免受栓塞影響,減少經導管主動脈瓣置換術、外科瓣膜置換術、心房顫動消融術和其它結構性心臟手術的腦梗塞風險。創新的設備旨在幫助介入性心臟病專家、電生理學家和心外科醫生在手術時保護腦儲備。
Keystone Heart 致力于通過創新的技術和臨床研究提高患者護理水平。TriGuard? 腦保護裝置(經導管主動脈瓣置換術)臨床研究目前仍在歐洲、加拿大和巴西進行。
Keystone Heart 與知名的介入性心臟病專家、心外科醫生和神經專家展開了合作。
該公司的管理層在介入性心臟病學和醫學設備方面擁有廣泛的經驗。
Keystone Heart 于2004年成立,總部位于以色列,由 OrbiMed Advisors LLC 和 OrbiMed Israel Partners 資助。該公司擁有和保持了廣泛的知識產權組合,并且獲得了 ISO 認證。
Keystone Heart Ltd is a medical device company developing and manufacturing cerebral protection devices to reduce the risk of stroke, neurocognitive decline and dementia caused by brain damage associated with cardiovascular procedures. The Company is focused on protecting the brain from emboli to reduce the risk of brain infarcts during TAVR, surgical valve replacement, atrial fibrillation ablation and other structural heart procedures. Novel devices are designed to help interventional cardiologists, electrophysiologists and cardiac surgeons to preserve brain reserve while performing these procedures.
Keystone Heart is dedicated to advancing patient care through innovative technology and clinical research. Clinical studies with the TriGuard? Cerebral Protection Device (TAVR procedures) are currently ongoing in Europe, Canada and Brazil.
Keystone Heart collaborates with renowned interventional cardiologists, cardiac surgeons and neurologists.
The Company’s management has extensive experience in the fields of interventional cardiology and medical devices.
Founded in 2004 and headquartered in Israel, Keystone Heart is funded by OrbiMed Advisors LLC and OrbiMed Israel Partners. The Company holds and maintains a comprehensive IP portfolio and is ISO certified.?